Anthropic Adds Novartis CEO Vas Narasimhan to Its Board — and That’s a Bigger Deal Than It Sounds

Anthropic just made a board appointment that tells you a lot about where they think AI is headed. Vas Narasimhan, the CEO of Novartis and a physician-scientist by training, is joining the company’s Board of Directors. He’s not just another tech exec — he’s spent years navigating one of the most heavily regulated industries on the planet, getting novel medicines approved and into the hands of patients.

Daniela Amodei put it well: “He’s overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries.” That’s not a skill set you see every day on an AI company’s board.

Here’s the part that actually matters for Anthropic’s governance structure. The appointment comes through the Long-Term Benefit Trust, an independent body whose members have no financial stake in Anthropic. With Narasimhan on board, Trust-appointed directors now hold a majority on the Board. That’s a deliberate move — the Trust exists to keep the company’s public benefit mission balanced against financial success, and having a majority means that balance isn’t just a talking point.

Narasimhan joins a board that already includes Dario and Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. Not bad company.

What makes this interesting is the specific expertise Narasimhan brings. Early in his career, he worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He’s an elected member of the US National Academy of Medicine. He chaired PhRMA, the pharmaceutical industry’s main lobbying group. This is someone who’s thought deeply about how to deploy powerful technology safely and at scale — exactly the kind of thinking Anthropic needs as Claude gets deployed in more sensitive contexts.

“Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic,” Amodei said. “Vas has been doing exactly that for years.”

Narasimhan himself seems to see the connection clearly: “In healthcare, AI is accelerating solutions to some of the hardest scientific challenges, from deepening our understanding of disease biology to designing better medicines.”

The timing makes sense. Healthcare and life sciences are among the areas where AI has the most obvious potential to improve human life, but they’re also areas where the consequences of getting it wrong are severe. Having someone on the board who’s dealt with FDA approvals, clinical trials, and global health disparities isn’t just a nice-to-have — it’s practical.

I’ll be curious to see whether this signals a more aggressive push into healthcare applications from Anthropic, or if it’s more about having the right governance in place as the company scales. Either way, it’s a smart hire. The Trust-appointed majority is the structural story here, but Narasimhan’s background is the one that actually changes what the board can do.